ABB Powers Tourists to the Niagara Falls with First US Built All-Electric Vessels
3.5.2019 18:45:00 EEST | Business Wire | Press release
Niagara Falls tour operator Maid of the Mist orders two new passenger vessels sailing on pure electric power, enabled by ABB’s technology
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190503005349/en/
Maid of the Mist new passenger vessels sailing on pure electric power, enabled by ABB's technology (Photo: Business Wire)
Visitors to the iconic Niagara Falls will soon be able to experience one of the US’s top landmarks emission-free. Two new Maid of the Mist passenger vessels will be powered entirely by high-capacity battery packs, becoming the first all-electric vessels ever built in the US.
The new vessels will benefit from ABB’s zero-emission technology when they start operating later this year, allowing guests to experience Niagara Falls undisturbed by engine noise, vibration or exhaust fumes from a conventional diesel engine.
Maid of the Mist, one of North America’s oldest tourist attractions, operates from April through to the first week of November, with boats departing for the base of Niagara Falls every 30 minutes, with an estimated 1.6 million guests on board annually.
“We are thrilled to be the US’s first vessel owner to add all-electric ferries to our fleet,” said Christopher M. Glynn, president of Maid of the Mist Corp. “We have chosen ABB to support us in our journey towards more sustainable operation based on their unparalleled experience in marine system integration, as well as efficient and innovative technologies for sustainable transportation.”
“Maid of the Mist’s decisive move towards e-mobility signals a new era in the future of transportation and complements ABB’s commitment to power the world without consuming the earth,” said Peter Terwiesch, President of the Industrial Automation business at ABB, which offers solutions for a wide range of industries, including marine. “Reducing emissions at Niagara Falls is not only important for the natural landmark, but also proves that the technologies enabling sustainable mobility are already available today.”
Each of the vessels will be powered by a pair of battery packs with a total capacity of 316 kWh, split evenly between two catamaran hulls. Having two fully independent power systems on board will increase the resilience of operations by creating a redundancy.
The vessels will charge between every trip while passengers disembark and board. Shoreside charging will only take seven minutes, allowing the batteries to power the electric propulsion motors capable of a total 400 kW (563 HP) output. The power setup will be controlled by ABB’s integrated Power and Energy Management System (PEMS), which will optimize the energy use on board.
The batteries will be charged using hydropower – the largest single renewable energy source for electricity generation in the US, which accounts for 7 percent of the country’s total utility-scale electricity generation. The use of locally produced renewable power will make the energy cycle for the operation of the new Maid of the Mist vessels entirely emission-free.
Sustainable transportation has a crucial role in the fight against climate change, with shipping accounting for 2 to 3 percent of the world’s total greenhouse gas emissions. The International Maritime Organization, a United Nations agency responsible for regulating shipping, has set a global target to cut annual emissions by at least 50 percent by 2050 from 2008 levels.
In addition to integrating the ship-to-shore battery charging connection, ABB will supply the Maid of the Mist newbuilding project with switchboards, drives and the integrated control system, as well as the ABB Ability™ Marine Remote Diagnostic System for remote equipment monitoring and predictive maintenance. ABB Ability™ is ABB’s leading offering of digital solutions and services.
To watch the video, click here.
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190503005349/en/
Contact information
ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland
Media
Relations
Phone: +41 43 317 71 11
Email: media.relations@ch.abb.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom